Acquired mutations that affect pre-mRNA splicing in hematologic malignancies and solid tumors.

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Next-generation sequencing reveals somatic mutations in human hematologic malignancies.
• Spliceosome mutations, affecting RNA processing, are identified in various cancers, including leukemia, myelodysplastic syndromes, and solid tumors like melanoma and lung and breast cancers.
• These mutations suggest a fundamental role in cancer development and progression.

Purpose of the Study:

• To summarize the effects of spliceosome mutations on transcript processing.
• To discuss the impact of these mutations on cancer initiation, progression, and patient outcomes.
• To explore therapeutic strategies targeting spliceosome mutations, particularly those in SF3B1.

Main Methods:

• Review of in vitro and in vivo studies on spliceosome-associated mutations.
• Analysis of next-generation sequencing data from various malignancies.
• Examination of therapeutic potential of SF3B1-targeting compounds.

Main Results:

• Spliceosome mutations are prevalent across diverse malignancies, influencing their molecular etiology.
• These mutations alter transcript processing, impacting cancer initiation and progression.
• SF3B1 is a frequently mutated spliceosome component, highlighting its therapeutic relevance.

Conclusions:

• Spliceosome mutations play a critical role in the pathogenesis of a wide range of cancers.
• Targeting spliceosome mutations, especially in SF3B1, represents a promising therapeutic avenue.
• Further research into spliceosome function and targeted therapies is warranted for improved cancer treatment.